Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, will present novel clinical and preclinical data on the mode of action of its lead clinical program.
Mendus publishes preclinical data demonstrating synergies of ilixadencel and 4-1BB-targeting immunotherapies finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.
Mendus appoints NK cell pioneer Lewis Lanier to Scientific Advisory Board streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Intratumoral injection of allogeneic pro-inflammatory dendritic cells ("ilixadencel") substantially and sustainably enhanced an otherwise ineffective systemic anti CTLA-4 treatment in an established in
COMBINATION OF CANCER RELAPSE VACCINE CANDIDATE WITH 5'-AZACITIDINE AND VENETOCLAX SHOWS SUPERIOR TUMOR REDUCTION IN AN AML MODEL Immunicum AB ("Immunicum" publ; IMMU.ST), a biopharmaceutical